William Annesley, MD
Urology · Wauwatosa, WINPI 1407899552
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Sanofi at 41.6% of the total. Reporting peaked in 2020 at $2,409 and has fallen 98.5% since, to $35 in 2025.
Across 46 payments — averaging $93.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Boston Scientific$515
- Healthtronics Stone Solutions, LLC$290
- Neotract Inc.$281
- Teleflex LLC$249
- Axonics, Inc.$240
- plus $932 from 11 others
What the payments were for
- Consulting fees$1,78842%
- Food & beverage$2,47858%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $1,788 |
| Boston Scientific | 8 | $515 |
| Healthtronics Stone Solutions, LLC | 4 | $290 |
| Neotract Inc. | 3 | $281 |
| Teleflex LLC | 4 | $249 |
| Axonics, Inc. | 4 | $240 |
| Rochester Medical Corporation | 5 | $192 |
| Pfizer | 4 | $151 |
| Astellas Pharma US Inc | 2 | $141 |
| Stryker | 1 | $129 |
| Medtronic | 1 | $116 |
| Johnson & Johnson | 3 | $69 |
| Agiliti Surgical, Inc. | 2 | $59 |
| Procept Biorobotics Corporation | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Coloplast | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,295 in reported general payments places this provider in the 75th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 61 | $50,838 |
| GemtesaVibegron | 61 | $47,786 |
| Tamsulosin Hcl | 555 | $7,076 |
| Finasteride | 656 | $6,787 |
| Solifenacin Succinate | 67 | $3,274 |
| Flavoxate Hcl | 16 | $1,655 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $1,072 |
| Dutasteride | 26 | $1,009 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 36 | $738 |
| Ciprofloxacin Hcl | 93 | $622 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 32 | $565 |
| Cephalexin | 19 | $134 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $101 |
| Amoxicillin | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $141 | $50,83861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 urology providers in Wisconsin.
Other urology in Wauwatosa
- Christopher WalshWauwatosa$21K
- Kohldon BoydstonWauwatosa$5K
- Dan GralnekMadison$142K
- Amy GuiseMilwaukee$106K
- Christopher ManakasMadison$87K
- Bahareh Alavi-DunnGreen Bay$62K
- Javier SantiagoMadison$57K
- Kevin FlynnNeenah$56K
- Margaret KnoedlerMadison$31K
- Jeremy ReesePleasant Prairie$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.